An analysis of monocytes and dendritic cells differentiated from human peripheral blood monocyte-derived induced pluripotent stem cells

Noriko Hiramatsu, Naoki Yamamoto, Sumito Isogai, Takanori Onouchi, Masaya Hirayama, Shingo Maeda, Takuma Ina, Masashi Kondo, Kazuyoshi Imaizumi

Research output: Contribution to journalArticle

Abstract

Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.

Original languageEnglish
JournalMedical Molecular Morphology
DOIs
Publication statusAccepted/In press - 01-01-2019

Fingerprint

Induced Pluripotent Stem Cells
Dendritic Cells
Monocytes
Mites
HLA-DR Antigens
Cell- and Tissue-Based Therapy
Immunotherapy
Genetic Recombination
Autoimmune Diseases
Hypersensitivity
Transplantation
Genome
Antigens
Mutation
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology

Cite this

@article{1c2bfa518d584692964d8d96a0307c14,
title = "An analysis of monocytes and dendritic cells differentiated from human peripheral blood monocyte-derived induced pluripotent stem cells",
abstract = "Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.",
author = "Noriko Hiramatsu and Naoki Yamamoto and Sumito Isogai and Takanori Onouchi and Masaya Hirayama and Shingo Maeda and Takuma Ina and Masashi Kondo and Kazuyoshi Imaizumi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00795-019-00231-8",
language = "English",
journal = "Medical Molecular Morphology",
issn = "1860-1480",

}

TY - JOUR

T1 - An analysis of monocytes and dendritic cells differentiated from human peripheral blood monocyte-derived induced pluripotent stem cells

AU - Hiramatsu, Noriko

AU - Yamamoto, Naoki

AU - Isogai, Sumito

AU - Onouchi, Takanori

AU - Hirayama, Masaya

AU - Maeda, Shingo

AU - Ina, Takuma

AU - Kondo, Masashi

AU - Imaizumi, Kazuyoshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.

AB - Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.

UR - http://www.scopus.com/inward/record.url?scp=85074441607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074441607&partnerID=8YFLogxK

U2 - 10.1007/s00795-019-00231-8

DO - 10.1007/s00795-019-00231-8

M3 - Article

C2 - 31584115

AN - SCOPUS:85074441607

JO - Medical Molecular Morphology

JF - Medical Molecular Morphology

SN - 1860-1480

ER -